From here.
Can be very interesting…
AstraZeneca's investigational TB drug in
Africa to determine its effectiveness as a potential new weapon against the
disease.
The Phase IIa study - which is being funded
by the National Institute of Allergy and Infectious Diseases (NIAID), part of
the US National Institutes of Health, and will involve 75 patients - is testing
the firm's AZD5847 against TB alone as well as in cases where there is
co-infection with HIV.
AZD5847 is an antibiotic active against
Gram-positive bacteria and mycobacteria, which has shown activity in culture
against a broad array of drug-sensitive and drug-resistant strains of
TB-causing mycobacterium tuberculosis, according to AZ.
Very
interesting structure. Hopefully it will work!
No comments:
Post a Comment